DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
Reference 26 (Meers) on the IDS submitted 11/04/2024 has been lined through and not considered. Only the first two pages of the reference appear to have been provided.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1, 2, 4-13, 15, 16, 19-21 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Fernandez (US 9,938,524).
Regarding claims 1 and 2, Fernandez taught:
A method for identifying a nucleic acid binding site of a target, the method comprising: (a) contacting the target that is bound to the nucleic acid binding site with a tagging composition, thereby binding the tagging composition to the target,
Col 3, line 33: “…extracting and fragmenting chromatin from a prepared sample, adding at least one antibody-oligonucleotide conjugate comprising an extraction moiety, allowing said antibody(ies) to locate at its/their target protein(s) in said chromatin fragments…”.
wherein the tagging composition comprises: (i) an antibody or an antibody fragment that binds to the target;
Col 3, line 33: “…extracting and fragmenting chromatin from a prepared sample, adding at least one antibody-oligonucleotide conjugate comprising an extraction moiety, allowing said antibody(ies) to locate at its/their target protein(s) in said chromatin fragments…”.
(ii) a heterocyclic compound that is linked to the antibody or the antibody fragment;
In Figure 6, Fernandez shows two embodiments for forming the antibody/oligonucleotide/transposase complex. On the left, the antibody is conjugated to transposase, and the transposase complexes with oligonucleotides that can be acted upon by the transposase to insert the oligonucleotides into nucleic acid targets bound to the protein recognized by the antibody. On the right, the antibody is conjugated to the oligonucleotides. In both cases, the antibody contains hydrazinonicotinamide (HyNic), and reacts with 4-formylbenzamide (4FB); see col 10, lines 40-50. The structure of hydrazinonicotinamide is:
2-hydrazinonicotinamide
PNG
media_image1.png
332
378
media_image1.png
Greyscale
or 6-hydrazinonicotinamide
PNG
media_image2.png
246
165
media_image2.png
Greyscale
Either one of these isomers is a heterocyclic compound. However, for purposes of this rejection, Fernandez taught an alternative coupling strategy. In Example 7, col 14-15, Fernandez taught:
“Any suitable chemistry can be used to achieve the antibody/oligonucleotide conjugations used in this invention. One such approach is described below. 1) The biotinylated forward strand oligonucleotide is annealed to the unbiotinylated reverse strand using standard procedures. 2) The antibody can be biotinylated using a number of available kits, for example, the Solulink Chromalink One-Shot biotinylation kit, which allows for quantitation of the number of biotins per antibody and thus allows for optimization of the number of biotins conjugated to the antibody. 3) Self assembly of the conjugate can be achieved by mixing appropriate ratios of the biotinylated oligo, biotinylated antibody, and free streptavidin, a tetramer with four biotin binding sites all of which can be simultaneously occupied.”
Biotin is a heterocyclic compound. In using this alternative coupling strategy to make the antibody-oligonucleotide complex, one would arrive at the limitation where the two or more nucleic acids (i.e. the two oligonucleotides shown in Fig. 6 coupled to the antibody) are attached to a heterocyclic compound (biotin) comprised by the antibody (via streptavidin).
(iii) a protein complex;
The streptavidin noted above is a protein complex. The biotin-streptavidin conjugation strategy additionally meets the limitations of claim 2.
and (iv) two or more nucleic acids that each comprise a barcode nucleotide sequence, wherein the two or more nucleic acids are linked to the heterocyclic compound;
As noted above, the biotin-streptavidin coupling strategy to make the antibody-oligonucleotide complex, one would arrive at the limitation where the two or more nucleic acids (i.e. the two oligonucleotides shown in Fig. 6 coupled to the antibody) are attached to a heterocyclic compound (biotin) comprised by the antibody (via streptavidin).
Col 6, line 67: “The inclusion of barcode sequences in the oligonucleotides allows for the identification of the corresponding immunoprecipitating antibody, and is the basis of the multi-analyte potential of TAM-ChIP, which for the first time enables simultaneous use of multiple antibodies in the same sample and experiment.”
and (b) contacting the two or more nucleic acids of the tagging composition with a transposase, thereby forming an antibody-barcode-transposase complex,
Col 3, line 42: “In some embodiments, the antibody-oligonucleotide conjugate further comprises transposase and the intermolecular reaction is transposition…”. See also Fig. 6.
wherein the antibody-barcode-transposase complex generates double stranded breaks in a nucleic acid comprising the nucleic acid binding site to generate a nucleic acid fragment comprising the nucleic acid binding site;
Col 3, line 42: “…transposition…”.
Col 5, line 46: “Transposase activation results in random insertion of the two transposase-associated oligonucleotides into the antibody-associated DNA fragment…”.
(c) isolating the nucleic acid fragment;
Col 4, line 20: “…tagging and isolating DNA or other nucleic acids that are associated with a protein or proteins of interest…”.
and (d) sequencing the nucleic acid fragment, thereby identifying the nucleic acid binding site of the target.
Col 6, line 55: “Following DNA purification to remove proteins, PCR amplification (or another suitable amplification process) with primers complementary to the oligonucleotides in the can be performed to generate NGS compatible libraries for sequencing.”
Col 12, line 50: “The ChIP-enriched and the untreated sonicated gDNA are processed according standard protocols for library preparation for sequencing in the Illumina Genome Analyzer GAIT. This consists of end-repair, adaptor ligation, size-selection and PCR amplification, and all these steps are done and sequencing performed according to standard methods. The generated data from both TAM-ChIP and traditional ChIP from two independent experiments is analyzed.”
See also Fernandez claims 20 and 24.
Regarding claims 4-6, Fernandez taught Tn5 transposase; see Fig. 6, for example. While Fernandez does not use the term “mosaic ends”, Fernandez used Tn5, and the oligonucleotides are able to be bound by Tn5 transposase and transposed into the targeted DNA. This could only happen if these oligonucleotides contained the “mosaic ends” recognized by Tn5. See also Fig. 1, which indicates “Tn5 rec. seq.”, and Fig. 3 “Transposase recognition sequence”.
Regarding claims 7-8, Fernandez taught targets including histone (a regulatory element) and polymerase (Fernandez claim 3). Fernandez also taught p53 (Example 1, col 7), which is a transcription factor.
Regarding claims 9 and 10, these limitations are met in the biotin-streptavidin conjugation of the oligonucleotides to the antibody taught in Fernandez Example 7.
Regarding claims 11-13, Fernandez taught (col 6, lines 48-59): “The samples are then diluted (to ensure transposition of the olig[o]nucleotide payload in the transposon cassette into the same DNA fragment) and the chromatin-associated-transposase activated by the addition of the Mg2+ co-factor, resulting in the insertion of the transposon cassette containing bar-code sequences and NGS compatible primer sites into flanking DNA regions (FIG. 1, Panel B). Following DNA purification to remove proteins, PCR amplification (or another suitable amplification process) with primers complementary to the oligonucleotides in the can be performed to generate NGS compatible libraries for sequencing.”
Regarding claims 15, 16 and 19-21, one arrives at the claimed composition by practicing the method of Fernandez, using the alternative biotin-streptavidin coupling strategy taught in Fernandez Example 7, as discussed above.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 22, 23 and 25 is/are rejected under 35 U.S.C. 103 as being unpatentable over Fernandez (US 9,938,524) in view of Polansky (US 2004/0023207) and Crabtree (US 2018/0305424).
The teachings of Fernandez have been discussed. Fernandez did not teach assembling the components required for practicing the methods into a “kit”, or separately placing the antibody-oligonucleotide conjugate and the transposase in separate containers.
Polansky taught (paragraph [0919]): “Well known advantages of commercial kits include convenience and reproducibility due to manufacturing standardization, quality control and validation procedures.”
Crabtree taught (para 0104): “The various reagent components of the kits may be present in separate containers, or some or all of them may be pre-combined into a reagent mixture in a single container, as desired.”
It would have been prima facie obvious to one of ordinary skill in the art prior to the effective filing date of the application to assemble the components for practicing Fernandez’s method into a kit to obtain the advantages of kits taught by Polansky. It would also have been obvious to package various components of Fernandez’s method in the same or separate containers as desired, as this was conventional in the art as evidenced by Crabtree, and does not represent an inventive concept.
Regarding claim 25, Fernandez taught the use of streptavidin magnetic beads to facilitate purification of targeted DNA (col 5, lines 20-26). Although Fernandez did not disclose this component used as a “cell capture scaffold”, it is nevertheless a magnetic bead, as well as a streptavidin bead, and is structurally indistinguishable from the magnetic bead and streptavidin bead as recited in the claim. The term “cell capture scaffold” is construed as an intended use.
Conclusion
No claims are free of the prior art.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMUEL C WOOLWINE whose telephone number is (571)272-1144. The examiner can normally be reached 9am-5:30pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, GARY BENZION can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SAMUEL C WOOLWINE/Primary Examiner, Art Unit 1681